Orthobiologics Market Is Expected To Reach a Revenue Of USD 11.7 Bn By 2033, at 5.7% CAGR: Dimension Market Research
11. November 2024 11:42 ET
|
Dimension Market Research
New York, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Market Overview Global Orthobiologics Market is projected to reach USD 7.1 billion by the end of 2024 and expand to USD 11.7 billion by 2033, with a...
Orthobiologics Market Set to Hit USD 14.2 Billion by 2033, Riding on a Strong 6.0% CAGR | Market.us
07. Februar 2024 04:27 ET
|
Market.Us
New York, Feb. 07, 2024 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Orthobiologics Market size is expected to be worth around USD 14.2 Billion by 2033 from USD 7.9...
Bone Graft Substitutes Market Set to Achieve USD 5.6 Billion Revenue by 2032 with 6.2% CAGR - Exclusive Report by Market.us
26. Mai 2023 00:34 ET
|
Market.Us
New York, May 26, 2023 (GLOBE NEWSWIRE) -- According to Market.us, the Gone Graft Substitutes Market size was valued at US$ 3.1 Bn in 2022 and is projected to attain a value of US$ 5.6 Bn by 2032....
DirectSync Surgical receives Breakthrough Device Designation from FDA for its Patient-Powered Smart Implants
02. Mai 2023 10:00 ET
|
DirectSync Surgical
LAWRENCE, Kan., May 02, 2023 (GLOBE NEWSWIRE) -- DirectSync Surgical, a medical device company dedicated to improving the lives of patients who suffer from spine and orthopedic diseases, has...
Global Bone Growth Stimulator Markets Trends, Opportunities, and Forecasts, 2018-2022 & 2022-2028
18. April 2023 10:53 ET
|
Research and Markets
Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Bone Growth Stimulator Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F: Segmented by Type (External Bone Growth...
Bone Growth Stimulator Market by Product, Application, End Users and Region - Global Forecast to 2027
28. Oktober 2022 05:03 ET
|
Research and Markets
Dublin, Oct. 28, 2022 (GLOBE NEWSWIRE) -- The "Bone Growth Stimulator Market by Product (Device (External Bone Growth Stimulators), Platelet-Rich Plasma), Application (Spinal Fusion Surgeries, Oral...
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
16. Mai 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
12. Mai 2022 08:00 ET
|
Entera Bio Ltd.
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
05. Mai 2022 08:00 ET
|
Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
Entera Bio to Report First Quarter 2022 Financial Results on May 12
28. April 2022 08:00 ET
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...